3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
3
Phase NA
1
Phase 4
1
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Conditions
Leukemia, Myeloid, Acute
22
Myelodysplastic Syndromes
18
Precursor Cell Lymphoblastic Leukemia-Lymphoma
13
Lymphoma
12
Leukemia
10
Multiple Myeloma
9
Hodgkin Disease
9
Neuroblastoma
8
Sarcoma
7
Lymphoma, Non-Hodgkin
6
Sarcoma, Ewing
5
Primary Myelofibrosis
5
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
5
Neoplasms, Plasma Cell
5
Leukemia, Lymphocytic, Chronic, B-Cell
5
Wilms Tumor
4
Rhabdomyosarcoma
4
Neuroectodermal Tumors, Primitive, Peripheral
4
Medulloblastoma
4
Lymphoma, Large B-Cell, Diffuse
4
Leukemia, Myelomonocytic, Chronic
4
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
4
Hematologic Neoplasms
4
Graft vs Host Disease
4
Congenital Abnormalities
4
Central Nervous System Neoplasms
4
Astrocytoma
4
Testicular Neoplasms
3
Retinoblastoma
3
Optic Nerve Glioma
3
Interventions
ibrutinib
3
Vincristine
2
Methotrexate
2
tozasertib
1
thymoglobulin
1
romiplostim
1
pembrolizumab
1
pegaspargase
1
palbociclib
1
obinutuzumab
1
lucatumumab
1
fludarabine
1
fenebrutinib
1
enzastaurin
1
duvelisib
1
Receptors, Chimeric Antigen
1
Prednisone
1
Prednisolone
1
Hydrocortisone
1
Hu-Mik-beta-1 monoclonal antibody
1
Doxorubicin
1
Dasatinib
1
Cytarabine
1
Cyclophosphamide
1
Busulfan
1
Azacitidine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Leukemia, Lymphoid
×
Busulfan
×
Clear all
NCT02916979
2023-10-18
FluBuATG
Dartmouth-Hitchcock Medical Center
Phase 1
Completed
20 enrolled